202 related articles for article (PubMed ID: 32591479)
1. Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal following a fixed-dose strategy.
Sobrino Jiménez C; Romero-Garrido JA; García-Martín Á; Quintana-Díaz M; Jiménez-Vicente C; González-Del Valle L; Herrero Ambrosio A; Benedí-González J
Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e66-e71. PubMed ID: 32591479
[TBL] [Abstract][Full Text] [Related]
2. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
Goldstein JN; Refaai MA; Milling TJ; Lewis B; Goldberg-Alberts R; Hug BA; Sarode R
Lancet; 2015 May; 385(9982):2077-87. PubMed ID: 25728933
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
[TBL] [Abstract][Full Text] [Related]
4. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
Bitonti MT; Rumbarger RL; Absher RK; Curran LM
J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
[TBL] [Abstract][Full Text] [Related]
6. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Sin JH; Berger K; Lesch CA
J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
[TBL] [Abstract][Full Text] [Related]
7. Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal: Does One Dose Fit All?
Schwebach AA; Waybright RA; Johnson TJ
Pharmacotherapy; 2019 May; 39(5):599-608. PubMed ID: 30892733
[TBL] [Abstract][Full Text] [Related]
8. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
[TBL] [Abstract][Full Text] [Related]
9. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate for Bleeding Complications of Vitamin K Antagonists-The PROPER3 Randomized Clinical Trial.
Abdoellakhan RA; Khorsand N; Ter Avest E; Lameijer H; Faber LM; Ypma PF; Nieuwenhuizen L; Veeger NJGM; Meijer K
Ann Emerg Med; 2022 Jan; 79(1):20-30. PubMed ID: 34535300
[TBL] [Abstract][Full Text] [Related]
10. Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials.
Milling TJ; Refaai MA; Sarode R; Lewis B; Mangione A; Durn BL; Harman A; Lee ML; Goldstein JN
Acad Emerg Med; 2016 Apr; 23(4):466-75. PubMed ID: 26822172
[TBL] [Abstract][Full Text] [Related]
11. Hemostatic Efficacy and Safety of Weight-Based Versus Fixed-Dose 4F-PCC for Vitamin K Antagonist Reversal.
Milkovits AE; Sugrue D; Faris J; Schad JL; McAllister KB
J Pharm Pract; 2024 Jan; ():8971900241228779. PubMed ID: 38241183
[No Abstract] [Full Text] [Related]
12. Safety and effectiveness of a prothrombin complex concentrate in approved and off-label indications.
Marcos-Jubilar M; García Erce JA; Martínez-Calle N; Páramo JA; Martínez Virto A; Quintana-Díaz M
Transfus Med; 2019 Aug; 29(4):268-274. PubMed ID: 31347218
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
Kuroski JE; Young S
Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
[TBL] [Abstract][Full Text] [Related]
14. Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants?
Mangram A; Oguntodu OF; Dzandu JK; Hollingworth AK; Hall S; Cung C; Rodriguez J; Yusupov I; Barletta JF
J Crit Care; 2016 Jun; 33():252-6. PubMed ID: 27021851
[TBL] [Abstract][Full Text] [Related]
15. Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice.
Desmettre T; Dehours E; Samama CM; Jhundoo S; Pujeau F; Guillaudin C; Hecquart C; Clerson P; Crave JC; Jaussaud R
Crit Care; 2012 Oct; 16(5):R185. PubMed ID: 23036234
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase 3b study.
Kushimoto S; Fukuoka T; Kimura A; Toyoda K; Brainsky A; Harman A; Chung T; Yasaka M
Int J Hematol; 2017 Dec; 106(6):777-786. PubMed ID: 28815410
[TBL] [Abstract][Full Text] [Related]
17. INR and vitamin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma.
Hood C; Goldstein JN; Milling TJ; Refaai MA; Bajcic P; Goldstein B; Sarode R
Blood Adv; 2023 May; 7(10):2206-2213. PubMed ID: 36574241
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage.
Rivosecchi RM; Durkin J; Okonkwo DO; Molyneaux BJ
Neurocrit Care; 2016 Dec; 25(3):359-364. PubMed ID: 27076286
[TBL] [Abstract][Full Text] [Related]
19. Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2.
Sarode R; Fukutake K; Yasaka M; Tortorici MA; Mangione A; Pfister M; Cuker A
Blood Adv; 2020 Sep; 4(17):4208-4216. PubMed ID: 32898246
[TBL] [Abstract][Full Text] [Related]
20. Use of four-factor prothrombin complex concentrate (4F-PCC) for management of bleeding not associated with therapeutic anticoagulant use.
Uttaro E; Young MR; Falvey J; Corvelli JM; Acquisto NM
Transfus Apher Sci; 2023 Oct; 62(5):103759. PubMed ID: 37453907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
